Pharmacologically, FGF-21 reduces body weight, increases insulin sensitivity, and reduces hepatic lipids in rodents. Preclinical studies suggest that FGF-21 may exert anti-inflammatory effects. We aimed to determine 1) whether endogenous FGF-21 provides protective effects against high-fat diet (HFD)-induced inflammation, and 2) whether low-dose administration of FGF-21 reverses HFD-induced inflammation and hepatic steatosis. In experiment #1, wild type (WT) and FGF-21-/- mice (n=8/group) were fed a HFD for 15 weeks. RT-PCR analysis showed that despite weighing slightly less than the WT mice, the FFG-21-/- mice were more susceptible to HFD-induced inflammation of the liver and white adipose tissue (WAT). To test whether administration of FGF-21 provides protection from HFD-induced inflammation, in Experiment #2, 20 male C57BL/6J mice were fed a HFD for 10 weeks. After 10 weeks of HFD feeding, mice were administered vehicle (saline + 0.1% BSA; n=10) or recombinant human FGF-21 (R and D Systems; n=10; 0.3 mg/kg/day) for 14 days via subcutaneous osmotic minipumps. There was no effect of FGF-21 administration on body weight. Histological analysis of WAT showed no effect of FGF-21 on adipocyte size, and no effect on crown-like structure number. Confirming this lack of effect of FGF-21 on inflammation, RT-PCR analyses of liver and WAT showed comparable mRNA expression of inflammatory markers, including Adgre1, Itgam, Itgax, Ccl2, Il1b, and Tnf in the vehicle- and FGF-21 treated groups. Despite having no effect on inflammation, FGF-21 significantly reduced fasting blood glucose levels. Histological evaluation of liver showed that low-dose FGF-21 administration improved nonalcoholic steatohepatitis score, attributed to decreased microvesicular steatosis.

In conclusion, endogenous FGF-21 confers some protection against obesity-induced inflammation, and low-dose FGF-21 administration decreases hepatic steatosis independent of changes in body weight.

Disclosure

S. Sharma: None. S. Jung: None. E. Graff: None. T.W. Gettys: None. D. Wanders: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.